In Vivo briefly describes these recently founded companies: Arch Therapeutics, Astute Medical, Cavadis, Constellation Pharmaceuticals, Curetis, and Traycer Diagnostic.

Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.